메뉴 건너뛰기




Volumn 34, Issue 4, 2006, Pages 277-279

Ziprasidone as coadjuvant treatment in resistant obsessive-compulsive disorder treatment

Author keywords

Obsessive compulsive disorder; Venlafaxine; Ziprasidone

Indexed keywords

CYCLOHEXANOL DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE; VENLAFAXINE; ZIPRASIDONE;

EID: 33746889835     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (8)

References (18)
  • 1
    • 0004859527 scopus 로고
    • Pharmacotherapy
    • Bellack AS, Hersen M, editores. New York: John Wiley and Sons
    • White K, Cole J. Pharmacotherapy. En: Bellack AS, Hersen M, editores. Handbook of comparative treatments. New York: John Wiley and Sons, 1990.
    • (1990) Handbook of Comparative Treatments
    • White, K.1    Cole, J.2
  • 4
    • 33746885419 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder
    • McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;59:472-3.
    • (2000) Arch Gen Psychiatry , vol.59 , pp. 472-473
    • McDougle, C.J.1    Epperson, C.N.2    Pelton, G.H.3    Wasylink, S.4    Price, L.H.5
  • 5
    • 1442284533 scopus 로고    scopus 로고
    • A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder
    • Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004;65:37-43.
    • (2004) J Clin Psychiatry , vol.65 , pp. 37-43
    • Denys, D.1    Van Megen, H.J.2    Van Der Wee, N.3    Westenberg, H.G.4
  • 6
    • 0028199065 scopus 로고
    • Clozapine and refractory obsessive-compulsive disorder: A case report
    • Young CR, Bostic JQ, McDonald CL. Clozapine and refractory obsessive-compulsive disorder: a case report. J Clin Psychopharmacology 1994;14:209-11.
    • (1994) J Clin Psychopharmacology , vol.14 , pp. 209-211
    • Young, C.R.1    Bostic, J.Q.2    McDonald, C.L.3
  • 7
    • 0029896442 scopus 로고    scopus 로고
    • Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder
    • Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-6.
    • (1996) J Clin Psychiatry , vol.57 , pp. 303-306
    • Saxena, S.1    Wang, D.2    Bystritsky, A.3    Baxter Jr., L.R.4
  • 9
    • 0036677162 scopus 로고    scopus 로고
    • Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: An open-label study
    • Denys D, Van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 2002;63:700-3.
    • (2002) J Clin Psychiatry , vol.63 , pp. 700-703
    • Denys, D.1    Van Megen, H.2    Westenberg, H.3
  • 10
    • 0030711107 scopus 로고    scopus 로고
    • Udate on pharmacologic management of OCD: Agents and augmentation
    • McDougle CJ. Udate on pharmacologic management of OCD: Agents and augmentation. J Clin Psychiatry 1997;58:11-7.
    • (1997) J Clin Psychiatry , vol.58 , pp. 11-17
    • McDougle, C.J.1
  • 11
    • 0035902983 scopus 로고    scopus 로고
    • Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile
    • Schmidt AW, Lebel LA, Howard HR. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201.
    • (2001) Eur J Pharmacol , vol.425 , pp. 197-201
    • Schmidt, A.W.1    Lebel, L.A.2    Howard, H.R.3
  • 12
    • 0036314871 scopus 로고    scopus 로고
    • Stimulation of 5-hydroxytryptamine (5-HT2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex
    • Pozzy L, Acconcia S, Ceglia I, Invernizzi RW, Samanin R. Stimulation of 5-hydroxytryptamine (5-HT2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem 2002;82:93-100.
    • (2002) J Neurochem , vol.82 , pp. 93-100
    • Pozzy, L.1    Acconcia, S.2    Ceglia, I.3    Invernizzi, R.W.4    Samanin, R.5
  • 13
    • 0036711059 scopus 로고    scopus 로고
    • SR46349-B, a 5-HT (2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens
    • Bonaccorso S, Meltzer HY, Li Z, Day J, Alboszta AR, Ichikawa J. SR46349-B, a 5-HT (2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 2002;27:430-41.
    • (2002) Neuropsychopharmacology , vol.27 , pp. 430-441
    • Bonaccorso, S.1    Meltzer, H.Y.2    Li, Z.3    Day, J.4    Alboszta, A.R.5    Ichikawa, J.6
  • 14
    • 0036848458 scopus 로고    scopus 로고
    • Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder
    • Bymaster FP, Katner JS, Nelson DL, Hemrik-Luecke SK, Threlkeld PG, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711.
    • (2002) Neuropsychopharmacology , vol.27 , pp. 699-711
    • Bymaster, F.P.1    Katner, J.S.2    Nelson, D.L.3    Hemrik-Luecke, S.K.4    Threlkeld, P.G.5
  • 15
    • 0033696731 scopus 로고    scopus 로고
    • Improving the treatment of schizophrenia: Focus on serotonin (5-HT1A) receptors
    • Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT1A) receptors. J Pharmacol Exp Ther 2000;295: 853-61.
    • (2000) J Pharmacol Exp Ther , vol.295 , pp. 853-861
    • Millan, M.J.1
  • 16
    • 0027439207 scopus 로고
    • Neurobiological mechanism involved in anti-depressant therapies
    • Briley M, Moret C. Neurobiological mechanism involved in anti-depressant therapies. Clin Neuropharmcol 1993;16:387-400.
    • (1993) Clin Neuropharmcol , vol.16 , pp. 387-400
    • Briley, M.1    Moret, C.2
  • 18
    • 0032979135 scopus 로고    scopus 로고
    • Pharmacological profile of neuroleptics at human monoamine transporters
    • Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacology 1999;368:277-83.
    • (1999) Eur J Pharmacology , vol.368 , pp. 277-283
    • Tatsumi, M.1    Jansen, K.2    Blakely, R.D.3    Richelson, E.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.